Trials / Completed
CompletedNCT04632862
The Efficacy and Safety of DWP16001 Compared to Placebo in the Treatment of Type 2 Diabetes Mellitus.
A Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase 3, Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of DWP16001 in Patients With Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 140 (actual)
- Sponsor
- Daewoong Pharmaceutical Co. LTD. · Industry
- Sex
- All
- Age
- 19 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and safety of DWP16001 compared to placebo in the treatment of type 2 diabetes mellitus.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DWP16001 | DWP16001 A mg |
Timeline
- Start date
- 2020-11-11
- Primary completion
- 2021-11-25
- Completion
- 2021-11-25
- First posted
- 2020-11-17
- Last updated
- 2022-10-25
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT04632862. Inclusion in this directory is not an endorsement.